Axsome Therapeutics (AXSM) vs ImmunityBio (IBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 290.0% versus a gain of 45.8%. Over five years, AXSM leads with a +331.3% price change compared with +4.8% for IBRX. ImmunityBio is the larger company by market cap ($10.50 billion vs $8.91 billion), about 1.2 times the size.
Axsome Therapeutics converts more of its revenue into profit, with a net margin of -28.7% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | IBRX |
|---|---|---|
| Share price | $170.08 | $9.91 |
| Market cap | $8.91B | $10.50B |
| 1-day change | -1.67% | +1.64% |
| YTD return | -5.29% | +392.42% |
| 1-year return | +45.79% | +290.00% |
| 5-year return | +331.35% | +4.84% |
| Forward P/E | 36.17 | — |
| EPS (TTM) | $-3.74 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $113.29M |
| Revenue growth (YoY) | +65.55% | +668.31% |
| Net income (latest FY) | $-183.17M | $-351.40M |
| Gross margin | 92.56% | 99.34% |
| Operating margin | -26.12% | -226.00% |
| Net margin | -28.69% | -310.18% |
| 52-week high | $260.19 | $12.43 |
| 52-week low | $118.71 | $1.95 |
| Distance from 52-week high | -34.63% | -20.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.35% | +28.66% |
| Average volume | 705.24K | 10.29M |
| Shares outstanding | 52.38M | 1.06B |
| Employees | 1,346 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed AXSM by 244.2 percentage points over the past year.
- Axsome Therapeutics is more profitable, keeping -28.7 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +65.55%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
AXSM vs IBRX FAQ
Which is bigger, Axsome Therapeutics or ImmunityBio?
ImmunityBio (IBRX) is larger, with a market capitalization of $10.50B compared with $8.91B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or IBRX?
IBRX returned +290.00% over the past 12 months, compared with +45.79% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and ImmunityBio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Axsome Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for ImmunityBio.